ArticleJournal of nanobiotechnology2026
Hypoxia-injured pulmonary vascular targeting and microenvironment-responsive nanoparticle to treat hypoxic pulmonary hypertension.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Hypoxic pulmonary hypertension (HPH) is characterized by sustained pulmonary vasoconstriction and vascular remodeling caused by chronic hypoxia. The vicious cycle between hypoxia-inducible factor-1α (HIF-1α) activation and reactive oxygen species (ROS) burst release plays a central role in disease progression. P-selectin is overexpressed on hypoxia-injured pulmonary vascular endothelial cells and pulmonary smooth muscle cells. Fucoidan (Fuco) is a high-affinity ligand for P-selectin. Based on this, a hypoxia-injured pulmonary vascular targeting drug delivery system siHIF-1α/PSS31@Fuco (HPF) was developed. HPF was able to target for hypoxia-injured pulmonary vascular endothelial cells and pulmonary smooth muscle cells via the P-selectin, then HPF was taken up by those cells via caveolin-1-dependent endocytosis. Subsequently, the ROS-triggered depolymerization of PSS31 ensured efficient cytosolic release of siHIF-1α and SS31 to efficiently inhibit the expression of HIF-1α and the production of ROS, respectively. In HPH rats, HPF alleviated pulmonary vascular remodeling and improved the hemodynamics and right ventricular function by breaking the vicious cycle between HIF-1α activation and ROS production. Therefore, HPF is a promising nanotherapeutic strategy for HPH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.